218 related articles for article (PubMed ID: 24260311)
1. Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.
Qin Q; Zhang C; Yang X; Zhu H; Yang B; Cai J; Cheng H; Ma J; Lu J; Zhan L; Liu J; Liu Z; Xu L; Sun X
PLoS One; 2013; 8(11):e79864. PubMed ID: 24260311
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
Qiu M; Yang X; Hu J; Ding X; Jiang F; Yin R; Xu L
PLoS One; 2013; 8(8):e72251. PubMed ID: 23977265
[TBL] [Abstract][Full Text] [Related]
3. The XPD Lys751Gln polymorphism has predictive value in colorectal cancer patients receiving oxaliplatin-based chemotherapy: a systemic review and meta-analysis.
Qian YY; Liu XY; Pei D; Xu JL; Shen H; Chen XF; Liu YQ; Shen LZ; Shu YQ
Asian Pac J Cancer Prev; 2014; 15(22):9699-706. PubMed ID: 25520091
[TBL] [Abstract][Full Text] [Related]
4. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Yang Y; Xian L
Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.
Zhang L; Ma W; Li Y; Wu J; Shi GY
Genet Mol Res; 2014 Jan; 13(1):228-36. PubMed ID: 24446315
[TBL] [Abstract][Full Text] [Related]
6. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
[TBL] [Abstract][Full Text] [Related]
7. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.
Yin M; Yan J; Voutsina A; Tibaldi C; Christiani DC; Heist RS; Rosell R; Booton R; Wei Q
Lung Cancer; 2011 Jun; 72(3):370-7. PubMed ID: 21075476
[TBL] [Abstract][Full Text] [Related]
8. Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
Cheng H; Qin Q; Sun X; Li F; Sun N; Cheng L; Lu Z; Chen B
Technol Cancer Res Treat; 2013 Oct; 12(5):473-82. PubMed ID: 23617284
[TBL] [Abstract][Full Text] [Related]
9. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.
Wu W; Li H; Wang H; Zhao X; Gao Z; Qiao R; Zhang W; Qian J; Wang J; Chen H; Wei Q; Han B; Lu D
PLoS One; 2012; 7(3):e33200. PubMed ID: 22479369
[TBL] [Abstract][Full Text] [Related]
10. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
[TBL] [Abstract][Full Text] [Related]
11. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Li XD; Han JC; Zhang YJ; Li HB; Wu XY
Asian Pac J Cancer Prev; 2013; 14(1):145-8. PubMed ID: 23534713
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: a systematic review and meta-analysis.
Ma Q; Qi C; Tie C; Guo Z
Gene; 2013 Nov; 530(2):309-14. PubMed ID: 23973729
[TBL] [Abstract][Full Text] [Related]
13. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.
Wei SZ; Zhan P; Shi MQ; Shi Y; Qian Q; Yu LK; Song Y
Med Oncol; 2011 Mar; 28(1):315-21. PubMed ID: 20143185
[TBL] [Abstract][Full Text] [Related]
15. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
Yao CY; Huang XE; Li C; Shen HB; Shi MQ; Feng JF; Pan LX; Tang JH
Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
[TBL] [Abstract][Full Text] [Related]
16. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
Booton R; Ward T; Heighway J; Taylor P; Power F; Ashcroft L; Morris J; Thatcher N
Cancer; 2006 Jun; 106(11):2421-7. PubMed ID: 16649224
[TBL] [Abstract][Full Text] [Related]
17. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
Li P; Wang YD; Cheng J; Chen JC; Ha MW
Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
[TBL] [Abstract][Full Text] [Related]
18. Association between XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma risk: a systematic review and meta-analysis.
Peng Q; Li S; Lao X; Chen Z; Li R; Qin X
Medicine (Baltimore); 2014 Dec; 93(29):e330. PubMed ID: 25546681
[TBL] [Abstract][Full Text] [Related]
19. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
Xiang T; Kang X; Gong Z; Bai W; Chen C; Zhang W
Cancer Chemother Pharmacol; 2017 Apr; 79(4):791-800. PubMed ID: 28314991
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
Lu X; Xiao S; Jin C; van der Straaten T; Li X
J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
